2024
Antimicrobial resistance (AMR), as defined by the WHO, occurs when bacteria, viruses, fungi, and parasites no longer respond to medications. This is a growing global health crisis because AMR makes infections harder to treat and increases the risk of disease spread,
2024
The PediCAP trial team is pleased to announce the successful completion of a series of dissemination meetings aimed at sharing trial results with key stakeholders in Mozambique. These meetings targeted a diverse audience,
2024
The PediCAP consortium, a global partnership of 14 institutions, presented promising results from its main trial, PediCAP-A, at the European Society of Clinical Microbiology and Infectious Diseases (ESCMID Global) conference held from April 27-30,
2023
The PediCAP project, dedicated to investigating antibiotic therapy for severe and very severe childhood community-acquired pneumonia, actively participated in the European & Developing Countries Clinical Trials Partnership (EDCTP) forum held in France from Nov 7-10,
2023
The PediCAP team is pleased to report that the 1100 patients required for the main trial in this study have now been recruited.
PediCAP is an innovative, EDCTP funded clinical trial,
2022
We are pleased to announce that the PediCAP trial have successfully passed its 25% recruitment milestone with more than 400 patients successfully randomised into their arms. PediCAP will determine whether children hospitalised for severe or very severe pneumonia,
2021
It’s impossible to ignore the Covid-19 pandemic and how it has gripped the lives of everyone around the world, but it is equally impossible to ignore the thousands of lives that are lost daily to chest infections (pneumonia).
2019
We are pleased to announce the launch of the brand new PediCAP project website!
Take a look at this new website, which describes the background,